HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Itagaki, K. Articles by Philpot, R. M. Search for Related Content PubMed PubMed Citation Articles by Itagaki, K. Articles by Philpot, R. M. Social Bookmarking                      What's this?

Volume 271, Number 33, Issue of August 16, 1996 pp. 20102-20107
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Expression and Characterization of a Modified Flavin-containing Monooxygenase 4 from Humans

(Received for publication, February 22, 1996, and in revised form, May 15, 1996)

From the Molecular Pharmacology Section, Laboratory of Cellular and Molecular Pharmacology, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709

The inability to obtain flavin-containing monooxygenase 4 (FMO4) in heterologous systems has hampered efforts to characterize this isoform of the FMO gene family. Neither the human nor the rabbit ortholog of FMO4, each of which has been cloned and sequenced, has been expressed. Attempts to achieve expression of FMO4 have been made with Escherichia coli, baculovirus, yeast, and COS systems.

The cDNAs encoding FMO4 have extended coding regions compared with those encoding other FMO isoforms. The derived amino acid sequences of FMO1, -2, -3, and -5 from all species examined contain about the same number of residues (531-535 residues), whereas the derived sequences of human and rabbit FMO4 contain 558 and 555 residues, respectively.

We have investigated whether the elongation of the FMO4 coding region is related to the inability to achieve expression. The cDNA encoding human FMO4 has been modified by a single base change that introduces a stop codon at the consensus position. This modification allows for expression in E. coli. Lack of expression of intact FMO4 is caused by a problem that occurs following transcription, a problem that is overcome completely by relocation of the stop codon 81 bases to 5 of its normal position. Truncated FMO4 is expressed as an active enzyme with characteristics typical of an FMO isoform.

Possible functional changes resulting from altering the 3-end of an FMO were investigated with human FMO3. Elongation of the coding region of the FMO3 cDNA to the next available stop codon (FMO3*) resulted in the expression of an enzyme with properties very similar to those of unmodified FMO3. Elongation of FMO3 lowered the level of expression in E. coli but did not eliminate it. As with FMO4, the difference in expression levels between FMO3 and elongated FMO3 (FMO3*) appears to be related to translation rather than transcription. The functional characteristics of FMO3 and FMO3* are not significantly different.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				B. V. Karanam, C. J. Welch, V. G. Reddy, J. Chilenski, M. Biba, and S. Vincent Drug Metab. Dispos., October 1, 2004; 32(10): 1061 - 1068. [Abstract] [Full Text] [PDF]

				V. Lattard, J. Zhang, and J. R. Cashman Alternative Processing Events in Human FMO Genes Mol. Pharmacol., June 1, 2004; 65(6): 1517 - 1525. [Abstract] [Full Text] [PDF]

				J. R. Cashman, V. Lattard, and J. Lin EFFECT OF TOTAL PARENTERAL NUTRITION AND CHOLINE ON HEPATIC FLAVIN-CONTAINING AND CYTOCHROME P-450 MONOOXYGENASE ACTIVITY IN RATS Drug Metab. Dispos., February 1, 2004; 32(2): 222 - 229. [Abstract] [Full Text] [PDF]

				B. Furnes, J. Feng, S. S. Sommer, and D. Schlenk Identification of Novel Variants of the Flavin-Containing Monooxygenase Gene Family in African Americans Drug Metab. Dispos., February 1, 2003; 31(2): 187 - 193. [Abstract] [Full Text] [PDF]

				J. C. Stevens, R. J. Melton, M. J. Zaya, and L. C. Engel Expression and Characterization of Functional Dog Flavin-Containing Monooxygenase 1 Mol. Pharmacol., February 1, 2003; 63(2): 271 - 275. [Abstract] [Full Text] [PDF]

				V. Lattard, C. Longin-Sauvageon, and E. Benoit Cloning, Sequencing and Tissue Distribution of Rat Flavin-Containing Monooxygenase 4: Two Different Forms Are Produced by Tissue-Specific Alternative Splicing Mol. Pharmacol., January 1, 2003; 63(1): 253 - 261. [Abstract] [Full Text] [PDF]

				S. K. Krueger, S. R. Martin, M.-F. Yueh, C. B. Pereira, and D. E. Williams Identification of Active Flavin-Containing Monooxygenase Isoform 2 in Human Lung and Characterization of Expressed Protein Drug Metab. Dispos., January 1, 2002; 30(1): 34 - 41. [Abstract] [Full Text] [PDF]

				B. J. Ring, S. A. Wrighton, S. L. K. Aldridge, K. Hansen, B. Haehner, and L. A. Shipley Flavin-Containing Monooxygenase-Mediated N-Oxidation of the M1-Muscarinic Agonist Xanomeline Drug Metab. Dispos., October 1, 1999; 27(10): 1099 - 1103. [Abstract] [Full Text]

				S. L. Ripp, K. Itagaki, R. M. Philpot, and A. A. Elfarra Species and Sex Differences in Expression of Flavin-Containing Monooxygenase Form 3 in Liver and Kidney Microsomes Drug Metab. Dispos., January 1, 1999; 27(1): 46 - 52. [Abstract] [Full Text]

				R. L. Haining, A. P. Hunter, A. J. M. Sadeque, R. M. Philpot, and A. E. Rettie BACULOVIRUS-MEDIATED EXPRESSION AND PURIFICATION OF HUMAN FMO3. Catalytic, Immunochemical, and Structural Characterization Drug Metab. Dispos., July 1, 1997; 25(7): 790 - 797. [Abstract] [Full Text]

				M. Tugnait, E. M. Hawes, G. McKay, A. E. Rettie, R. L. Haining, and K. K. Midha N-Oxygenation of Clozapine by Flavin-Containing Monooxygenase Drug Metab. Dispos., April 1, 1997; 25(4): 524 - 527. [Abstract] [Full Text]